Healthcare Biz Recap: AmerisourceBergen’s GOOD News, Pfizer SURVIVES FDA Request

AmerisourceBergen Corporation (NYSE:ABC) is now the wholesale drug provider to Express Scripts, Inc. (NASDAQ:ESRX), as the latter replaces Cardinal Health Inc. (NYSE:CAH) with the former, in a three-year agreement with a yearly value of $18.5 billion. Further, Amerisource forecasts that the arrangement should contribute about 23 percent of its revenue and 3 percent of its earnings per share, but it will not impact the company’s outlook for its fiscal year 2012 or fiscal year 2013.

Don’t Miss: Does Coach’s 19% CRASH Say Something About the U.S. Economy?

Zalicus Inc (NASDAQ:ZLCS) shares move up modestly on a glowing review of its Z160 & Z944 calcium channel blockers, by blogger Ramsay Schrum. The blockers have the potential to create the first pain management medication that is orally administered without the abuse and addictive side effects may accompany the use of opioids, according to Schrum.

Shares of Pfizer Inc. (NYSE:PFE) survive a dreaded FDA request for additional analysis of existing data in its tofacitinib New Drug Application, according to the firm’s earnings call. The company intends to release this information early in August and now anticipates that the agency may well need additional time beyond the August 21 Prescription Drug User Fee Act date to review.

Don’t Miss: Pfizer Earnings: Profit Jump BREAKS Streak of Falling Profits.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.